dsp 4 has been researched along with Parkinson Disease in 13 studies
DSP 4: RN given refers to parent cpd
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Paradoxically, these prodromal symptoms are indicative of a noradrenergic hyperactivity phenotype, rather than the predicted loss of norepinephrine (NE) transmission following LC damage, suggesting the engagement of complex compensatory mechanisms." | 1.91 | The Neurotoxin DSP-4 Dysregulates the Locus Coeruleus-Norepinephrine System and Recapitulates Molecular and Behavioral Aspects of Prodromal Neurodegenerative Disease. ( Dougherty, JD; Iannitelli, AF; Kelberman, MA; Korukonda, A; Liles, LC; Lustberg, DJ; McCann, KE; Mulvey, B; Segal, A; Sloan, SA; Weinshenker, D, 2023) |
| "Tremor was assessed visually and with accelerometers." | 1.91 | Brain Noradrenergic Innervation Supports the Development of Parkinson's Tremor: A Study in a Reserpinized Rat Model. ( Asan, E; Biella, GEM; Bolzoni, F; Cavallari, P; Ip, CW; Isaias, IU; Pezzoli, G; Pozzi, NG; Volkmann, J, 2023) |
| "BACKGROUND AND PURPOSE Parkinson's disease (PD) is characterized by progressive dopaminergic cell loss; however, the noradrenergic system exhibits degeneration as well." | 1.38 | Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit. ( Giordano, G; Harkavyi, A; Lever, R; Rampersaud, N; Whitton, J; Whitton, P, 2012) |
| "Dopaminergic lesion produced catalepsy and hypoactivity." | 1.32 | Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. ( Schmidt, WJ; Srinivasan, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Iannitelli, AF | 1 |
| Kelberman, MA | 1 |
| Lustberg, DJ | 1 |
| Korukonda, A | 1 |
| McCann, KE | 1 |
| Mulvey, B | 1 |
| Segal, A | 1 |
| Liles, LC | 1 |
| Sloan, SA | 1 |
| Dougherty, JD | 1 |
| Weinshenker, D | 1 |
| Torrente, D | 1 |
| Su, EJ | 1 |
| Schielke, GP | 1 |
| Warnock, M | 1 |
| Mann, K | 1 |
| Lawrence, DA | 1 |
| Pozzi, NG | 1 |
| Bolzoni, F | 1 |
| Biella, GEM | 1 |
| Pezzoli, G | 1 |
| Ip, CW | 1 |
| Volkmann, J | 1 |
| Cavallari, P | 1 |
| Asan, E | 1 |
| Isaias, IU | 1 |
| Song, S | 1 |
| Wang, Q | 1 |
| Jiang, L | 1 |
| Oyarzabal, E | 1 |
| Riddick, NV | 1 |
| Wilson, B | 1 |
| Moy, SS | 1 |
| Shih, YI | 1 |
| Hong, JS | 1 |
| Shin, E | 1 |
| Rogers, JT | 1 |
| Devoto, P | 1 |
| Björklund, A | 1 |
| Carta, M | 1 |
| Wang, Y | 1 |
| Wang, HS | 1 |
| Wang, T | 1 |
| Huang, C | 1 |
| Liu, J | 1 |
| Yao, N | 1 |
| Wu, Y | 1 |
| Zhou, Y | 1 |
| Ju, L | 1 |
| Liu, Y | 1 |
| Ju, R | 1 |
| Duan, D | 1 |
| Xu, Q | 1 |
| Ledreux, A | 1 |
| Boger, HA | 1 |
| Hinson, VK | 1 |
| Cantwell, K | 1 |
| Granholm, AC | 1 |
| Cao, LF | 1 |
| Peng, XY | 1 |
| Huang, Y | 1 |
| Wang, B | 1 |
| Zhou, FM | 1 |
| Cheng, RX | 1 |
| Chen, LH | 1 |
| Luo, WF | 1 |
| Liu, T | 1 |
| Rampersaud, N | 1 |
| Harkavyi, A | 1 |
| Giordano, G | 1 |
| Lever, R | 1 |
| Whitton, J | 1 |
| Whitton, P | 1 |
| Srinivasan, J | 1 |
| Schmidt, WJ | 1 |
| Jonsson, G | 1 |
| Magyar, K | 1 |
| Szende, B | 1 |
| Lengyel, J | 1 |
| Tarczali, J | 1 |
| Szatmáry, I | 1 |
2 reviews available for dsp 4 and Parkinson Disease
| Article | Year |
|---|---|
Chemical neurotoxins as denervation tools in neurobiology.
Topics: 5,6-Dihydroxytryptamine; 5,7-Dihydroxytryptamine; Animals; Benzylamines; Brain; Catecholamines; Dene | 1980 |
The neuroprotective and neuronal rescue effects of (-)-deprenyl.
Topics: Animals; Antiparkinson Agents; Benzylamines; Biotransformation; Brain; Humans; Melanoma; Neurons; Ne | 1998 |
11 other studies available for dsp 4 and Parkinson Disease
| Article | Year |
|---|---|
The Neurotoxin DSP-4 Dysregulates the Locus Coeruleus-Norepinephrine System and Recapitulates Molecular and Behavioral Aspects of Prodromal Neurodegenerative Disease.
Topics: Animals; Female; Locus Coeruleus; Male; Mice; Neurodegenerative Diseases; Neurotoxins; Norepinephrin | 2023 |
Opposing effects of β-2 and β-1 adrenergic receptor signaling on neuroinflammation and dopaminergic neuron survival in α-synuclein-mediated neurotoxicity.
Topics: alpha-Synuclein; Animals; Dopaminergic Neurons; Humans; Mice; Nerve Degeneration; Neuroinflammatory | 2023 |
Brain Noradrenergic Innervation Supports the Development of Parkinson's Tremor: A Study in a Reserpinized Rat Model.
Topics: Animals; Brain; Humans; Male; Norepinephrine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reserpi | 2023 |
Noradrenergic dysfunction accelerates LPS-elicited inflammation-related ascending sequential neurodegeneration and deficits in non-motor/motor functions.
Topics: Adrenergic Neurons; Aging; Animals; Benzylamines; Brain; Disease Models, Animal; Dopaminergic Neuron | 2019 |
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Adrenergic Neurons; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benz | 2014 |
L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzylamines; Chromatography, High Pressure Liquid | 2014 |
Lesion of the locus coeruleus aggravates dopaminergic neuron degeneration by modulating microglial function in mouse models of Parkinson׳s disease.
Topics: Adrenergic Agents; Animals; Benzylamines; Calcium-Binding Proteins; Cells, Cultured; Coculture Techn | 2015 |
BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson׳s disease.
Topics: Animals; Behavior, Animal; Benzylamines; Brain; Brain-Derived Neurotrophic Factor; Chaperonin 60; Co | 2016 |
Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease.
Topics: Animals; Benzylamines; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Norepinephrine; Oxid | 2016 |
Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.
Topics: Animals; Behavior, Animal; Benzylamines; Cerebrum; Disease Models, Animal; Dopamine; Exenatide; Male | 2012 |
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Basal | 2004 |